Aclarion CEO Brent Ness to Attend LSI USA 2026

Core Insights - Aclarion, Inc. is participating in LSI USA 2026 to discuss advancements in its proprietary MR spectroscopy platform, NOCISCAN, aimed at addressing chronic low back pain [1][2]. Company Overview - Aclarion is a commercial-stage healthcare technology company utilizing biomarkers and augmented intelligence algorithms to assist physicians in identifying chronic low back pain [1]. - The company’s NOCISCAN platform is the first evidence-supported SaaS solution designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [3]. Product Details - NOCISCAN employs Magnetic Resonance Spectroscopy (MRS) to analyze data from MRI machines, extracting chemical biomarkers associated with disc pain [3]. - The platform integrates proprietary signal processing techniques and algorithms to provide insights into the source of a patient's low back pain, aiding in treatment optimization [3]. Event Participation - Brent Ness, CEO of Aclarion, will attend LSI USA 2026 from March 16-20, 2026, in Dana Point, CA, to engage with investors and industry partners [2][3]. - The event focuses on accelerating innovation in MedTech and HealthTech, bringing together key stakeholders in the industry [3].